Malnutrition of Affluence

With the advent of a highly processed American diet and changes in our eating habits since World War II, the consumption of essential plant-derived nutrients (phytonutrients) is on the decline. Despite consumer and physician awareness about the importance of eating a diverse diet many of the same forces that are contributing to the epidemics of obesity, cardiovascular disease and diabetes contribute to the poor dietary state of Americans today.  The fact that these "orphaned phytonutrients" are depleted from American's diet may be responsible (in part) for causing or worsening chronic diseases such as diabetes and cardiovascular disease.

Based on this association and the preponderance of epidemiologic evidence, Galileo's nutritional development strategy is to identify depleted beneficial plant-based bioactive phytonutrients and to replace them in supplement and food ingredient form to combat inflammatory mediated diseases. This discovery and development parallels Galileo's pharmaceutical programs in target validation and aggregation of data.

Galileo's product strategy is to apply its technology platform to develop bioactive Nutrient Ingredient Systems™ targeting at-risk healthy consumers and select affected patient populations. Since Galileo's initial focus is on nutritional products, the Company can generate revenue and profit much earlier in the product development lifecycle than a traditional biotechnology firm. Clinical data gained within nutritional programs about both ingredient system activity and biomarker response profiles are being incorporated into the Company's pharmaceutical programs. As the company continues to advance its research in the future, the sales and profits from high value nutritional supplements and functional foods will be used to fund research on even higher value pharmaceuticals.

Galileo relies on partnerships with pharmaceutical and consumer goods companies to bring its products to market. The Company currently has marketing and development partnerships established with leading companies in the pharmaceutical, raw material and consumer product sectors.

Galileo's business development strategy is to widen its core technology platform by accessing enabling technologies from key biotechnology partners. The Company currently has multiple non-disclosed technology licensing deals. The Company will commercialize clinically proved, proprietary nutritional products through market leaders. The Company will retain pharmaceutical rights through completion of Phase II trials for its drug products. Galileo has peer reviewed grants awarded by the Florida Department of Citrus and the National Oceanic and Aviation Administration. In addition, Galileo has key collaborations with investigators at Johns Hopkins, Harvard, University of California, Berkeley and other academic institutions.